Type I interferons and their therapeutic role in Th2-regulated inflammatory disorders

Bibliography

• ISAACS A, LINDENMANN J: Virus interference. I. The interferon. Proc. R. Soc. London Ser. B(1957) 147(927):258–267.
   PubMed Web of Science ®Google Scholar
• GUTTERMAN JU: Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. ScL USA (1995) 91:1198–1205.
   Web of Science ®Google Scholar
• BELARDELLI F, GRESSER I: The neglected role of type I interferon in the T-cell response: implications for its clinical use. bronunol Today(1996) 17:369–372.
   PubMed Web of Science ®Google Scholar
• TILG H: New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology (1997) 112:1017–1021.
   PubMed Web of Science ®Google Scholar
• BEIGNON A-S, SKOBERNE M, BHARDWAJ N: Type I interferons promote cross-priming: more functions for old cytokines. Nat. bronunol. (2003) 4:939–941.
   PubMed Web of Science ®Google Scholar
• MOUSALLI J, OPOLON P, POYNARD T: Management of hepatitis C. I Viral Hepat.. (1998) 5:73–82.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, TALPAZ M, O'BRIEN S et al.: Chronic myelogenous leukemia - progress at the M.D. Andersen Cancer Centre over the past two decades and future directions: first Emil J Freireich Award Lecture. Clin. Cancer Res. (1997) 3:2723–2733.
   Google Scholar
• NO AUTHORS LISTED: Placebo-controlled multicentre randomised trial on interferon beta-lb in treatment of secondary progressive multiple sclerosis. European Study Group on interferonB-lb in secondary progressive MS. Lancet (1998) 352:1491–1497.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS Study Group. Lancet (1998) 352:1498–1504.
   PubMed Web of Science ®Google Scholar
• STEWART TA, HULTGREN B, HUANG X, PITTS-MEEK S, HULLY J, MACLACHLAN NJ: Induction of type I diabetes by interferon-alpha in transgenic mice. Science (1993) 260: 1942–1946.
   PubMed Web of Science ®Google Scholar
• ROGGE L, DAMBROSIO, BIFFI M et a/.: The role of Stat4 in species-specific regulation of Th cell development by type I IFNs.J bronunol. (1998) 161(12):6567–6574.
   Google Scholar
• DEMEURE CE, WU CY, SHU U et al: In vitro maturation of human neonatal CD4 T lymphocytes. Cytokines present at priming modulate the development of lymphokine production.j Irronunol (1994) 152(10):4775–4782.
   Google Scholar
• PASSOS DE SOUZA E, EVANGELISTA SEGUNDO PT, JOSE FE LEMAIRE D, SANTIAGO M: Rheumatoid arthritis induced by alpha-interferon therapy. Clin. Awn-bawl (2001) 20(4):297–299.
   Google Scholar
• PINTO JM, MARQUES MS, CORREIA TE: Lichen planus and leukocytoclastic vasculitis induced by interferon-alpha-2b in a subject with HCV-related chronic active hepatitis.' Ear: Acad. Dermatol Venereol (2003) 17(2):193–195.
   Google Scholar
• BRINKMANN V, GEIGER T, ALKAN S, HEUSSER CH: Interferon alpha increases the frequency of interferon-gamma producing human CD4+ T cells. I Exp. Med. (1993) 178:1655–1663.
   PubMed Web of Science ®Google Scholar
• KASER A, MOLNAR C, TILG H: Differential regulation of interleukin 4 and interleukin 13 production by interferon alpha. Cytokine (1998) 10:75–81.
   PubMed Web of Science ®Google Scholar
• •Demonstrates suppression of a major Th2 cytokine, namely IL-13 by IFN-a.
   Google Scholar
• DICKENSHEETS HL, VENKATARAMAN C, SCHINDLER U, DONNELLY RP: Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc. Natl. Acad. Sci. USA (1999) 96:10800–10805.
   PubMed Web of Science ®Google Scholar
• WILLS-KARP M, LUYIMBAZI J, XU Xet al.: Interleukin-13: central mediator of allergic asthma. Science (1998) 282:2258–2261.
   Google Scholar
• •Highlights the central role of IL-13 in allergic asthma as the basic rationale for clinical studies with type I IFNs in this disease.
   Google Scholar
• HELLER F, BOIRIVANT M, MANNON P et al: IL-13 secretion by CD4+CD161+ NK-T cells is increased in oxazolone and human ulcerative colitis (UC). Gastroenterology (2003) 124:A-35 (abstract 276).
   Google Scholar
• •Identifies the role of IL-13 in another Th2-related disorder, namely UC.
   Google Scholar
• HUBER C, BATCHELOR JR, FUCHS D et al: Immune-response associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. Exp. Med. (1984) 160:310–316.
   Google Scholar
• CORSSMIT EP, HEIJLIGENBERG R, HACK CE, ENDERT E, SAUERWEIN HP, ROMIJN JA: Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin. Exp. bronunol. (1997) 107:359–363.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA: Biologic basis for interleukin-1 in disease. Blood (1996) 87:2095–2147.
   PubMed Web of Science ®Google Scholar
• SCHINDLER R, GHEZZI P, DINARELLO CA: IL-1 induces IL-1. IV IFN-gamma suppresses IL-1- but not lipopolysaccharide-induced transcription of IL-1. J. Innnunol. (1990) 144:2216–2222.
   Google Scholar
• TILG H, MIER JVV, VOGEL W et al: Induction of circulating IL-1 receptor antagonist by IFN treatment. Innnunol. (1993) 150:4687–4692.
   Google Scholar
• •First evidence of induction of a prototype anti-inflammatory cytokine by IFN-a.
   Google Scholar
• HUANG Y, BLATT LM, TYLOR MW: Type I interferon as an anti-inflammatory agent: inhibition of lipopolysaccharide-induced interleukin-1 beta and induction of interleukin-1 receptor antagonist. .1. Interferon Cytokine Res. (1995) 15:317–323.
   PubMed Web of Science ®Google Scholar
• AULITZKY WE, PESCHEL C, DESPRES D et al: Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukaemia. Ann. Heinatol (1993) 67:205–211.
   PubMed Web of Science ®Google Scholar
• REZNIKOV LL, PUREN AJ, FANTUZZI G et al.: Spontaneous and inducible cytokine responses in healthy humans receiving a single dose of IFN-alpha 2b: increased production of interleukin-1 receptor antagonist and suppression of IL-1-induced IL-8. I Interferon Cytokine Res. (1998) 18:897–903.
   PubMed Web of Science ®Google Scholar
• OLIVEIRA IC, SCUAVOLINO PJ, LEE TH, VILCEK J: Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc. Natl. Acad. Sci. USA (1992) 89:9049–9053.
   PubMed Web of Science ®Google Scholar
• AMAN MJ, RUDOLF G, GOLDSCHMITT G et al.: Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood (1993) 82:2371–2378.
   PubMed Web of Science ®Google Scholar
• OLIVEIRA IC, MUKAIDA N, MATSUSHIMA K, VILCEK J: Transcriptional inhibition of the interleukin-8 gene by interferon is mediated by the NF-kappa B site. Ma Cell. Biol (1994) 14:5300–5308.
   Web of Science ®Google Scholar
• BEMELSMANS MH, VAN TITS LJ, BUURMAN WA: Tumor necrosis factor: function, release and clearance. Grit. Rev bronunol (1996) 16:1–11.
   PubMed Web of Science ®Google Scholar
• OLSSON I, GATANAGA T, GULLBERG U, LANTZ M, GRANGER GA: Tumour necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur. Cytokine Netsv (1993) 4:169–180.
   PubMed Web of Science ®Google Scholar
• ABU-KHABAR KS, ARMSTRONG JA, HO M: Type I interferons (IFN-alpha and -beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cell. J. Leukoc. (1992) 52:165–172.
   PubMed Web of Science ®Google Scholar
• LARREA E, GARCIA N, QJAN C, CIVIERA MP, PRIETO J: Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology (1996) 23:210–217.
   PubMed Web of Science ®Google Scholar
• TILG H, VOGEL W, DINARELLO CA: Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans. Blood (1995) 85:433–435.
   PubMed Web of Science ®Google Scholar
• MOORE KW, O& GARRA A, DE WAAL MALEFYT R, VIEIRA P, MOSMANN TR: Interleukin- 10. Ann. Rev bronunol (1993) 11:165–190.
   PubMedGoogle Scholar
• KOHN R, LOHLER J, RENNICK D, RAJEWSKY K, MOLLER W: Interleuldn-10-deficient mice develop chronic enterococlitis. Cell (1993) 75:263–274.
   PubMed Web of Science ®Google Scholar
• AMAN MJ, TRETTER T, EISENBEIS I et al.: Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood (1996) 87:4731–4736.
   PubMed Web of Science ®Google Scholar
• CURRELI S, ROMERIO F, SECCHIERO P, ZELLA D: IFN-alpha2b increases interleukin-10 expression in primary activated human CD4+ T cells. Interferon Cytokine Res. (2002) 22(12):1167–1173.
   PubMed Web of Science ®Google Scholar
• MCRAE BL, PICKER LJ, VAN SE VENTER GA: Human recombinant interferon-beta influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors. Ear: IrninunoL (1997) 27:2650–2656.
   PubMed Web of Science ®Google Scholar
• LEVINGS MK, SANGREGORIO R, GALBIATI F et al: IFN-alpha and IL-10 induce the differentiation of human type T regulatory cells. Innnunol. (2001) 166(9):5530–5539.
   Google Scholar
• TZUNG SP, MAHL TC, LANCE P, ANDERSEN V, COHEN SA: Interferon-alpha prevents endotcodn-induced mortality in mice. Eur. Innnunol. (1992) 22:3097–3101.
   PubMed Web of Science ®Google Scholar
• GISSLINGER H, SVOBODA T, CLODI M et al.: Interferon-alpha stimulates the hypothalamic-pituitary axis in vivo and in vitro. Neuroendocrinology (1993) 57:489–495.
   PubMed Web of Science ®Google Scholar
• OKADA AA, KEINO H, SUZUKI J, SAKAI J, USUI M, MIZUGUCHI J: Kinetics of intraocular cytokines in the suppression of experimental autoimmune uveoretinitis by type I IFN. Int. Innnunol. (1998) 10:1917–1922.
   PubMed Web of Science ®Google Scholar
• SOBEL DO, AHVAZI B: Alpha-interferon inhibits the development of diabetes in NOD mice. Diabetes (1998) 47:1867–1872.
   PubMed Web of Science ®Google Scholar
• FLORIS S, RUULS SR, WIERINCKX A et al.: Interferon-beta directly influences monocyte infiltration into central nervous system. Neuroinonunol (2002) 127(1-2):69–79.
   PubMed Web of Science ®Google Scholar
• KASER A, NOVICK D, RUBINSTEIN M et al.: Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin. Exp. Innnunol. (2002) 129:332–338.
   PubMed Web of Science ®Google Scholar
• COHEN JJ: Apoptosis. bronunol. Today (1993) 14:126–130.
   Google Scholar
• NAGATA S: Apoptosis by death factor. Cell (1997) 88:355–365.
   PubMed Web of Science ®Google Scholar
• SUDA T, TAKAHAHI T, GOLSTEIN P, NAGATA S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell (1993) 75:1169–1178.
   PubMed Web of Science ®Google Scholar
• TANAKA M, SUDA T, TAKAHASHI T, NAGATA S: Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBDI. (1995) 14:1129–1135.
   PubMed Web of Science ®Google Scholar
• VAN DEVENTER SJH: Tumour necrosis factor and Crohn's disease. Cut (1997) 40:443.
   Google Scholar
• KABELITZ D, POHL D, PECHHOLD K: Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. bronunol. Today (1993) 14:338–339.
   PubMed Web of Science ®Google Scholar
• BRUNNER T, MOGIL RJ, LAFACE D et al.: Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature (1995) 373:441–444.
   PubMed Web of Science ®Google Scholar
• DHEIN J, WALCZAK H, BAUMLER C, KRAMMER PH: Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature (1995) 373:438–441.
   PubMed Web of Science ®Google Scholar
• JUST, PANKA DJ, CUI H et al: Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature (1995) 373:444–448.
   PubMed Web of Science ®Google Scholar
• KASER A, NAGATA S, TILG H: Interferon alpha augments activation-induced T-cell death by upregulation of Fas (CD95/AP0-1) and Fas ligand expression. Cytokine (1999) 11:736–743.
   PubMed Web of Science ®Google Scholar
• •First paper demonstrating the proapoptotic effects of a type I IFN.
   Google Scholar
• KAYAGAKI N, YAMAGUCHI N, NAKAYAMA M, ETO H, OKUMURA K, YAGITA H: Type I interferons (IFNs) regulate tumor-necrosis factor related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. I Exp. Merl (1999) 189(9):1451–1460.
   PubMed Web of Science ®Google Scholar
• MARRACK P, KAPPLER J, MITCHELL T: Type I interferons keep activated T cells alive. I Exp. Med. (1999) 189(3):521–530.
   PubMed Web of Science ®Google Scholar
• HIRSCH RL, JOHNSON KP: The effects of long-term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation and suppressor cell function in multiple sclerosis. Interferon Res. (1986) 6:171–177.
   PubMedGoogle Scholar
• AULITZKY WE, TILG H, VOGEL W et al.: Acute hematological effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin-2. Ann. Heinatol (1991) 62:25–31.
   PubMed Web of Science ®Google Scholar
• PENDER MP: Genetically determined failure of activation-induced apoptosis of autoreactive T-cells as a cause of multiple sclerosis. Lancet (1998) 351:978–981.
   PubMed Web of Science ®Google Scholar
• •Major hypothesis paper suggesting that impaired AICD might be of relevance in MS.
   Google Scholar
• KASER A, DEISENHAMMER F, BERGER T, TILG H: Interferon beta lb augments activation-induced T-cell death in multiple sclerosis patients. Lancet (1999) 353:1413–1414.
   PubMed Web of Science ®Google Scholar
• FATTOVICH G, GIUSTINA G, FAVAROTO S, RUOL A: A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. Hepatol (1996) 24:38–47.
   PubMed Web of Science ®Google Scholar
• SIMON H, ALAM R: Regulation of eosinophilic apoptosis: transduction of survival and death signals. hat. Arch. Allergy Iminunol. (1999) 118:7–14.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA H, NAKAO A, WATANABE Y, YOSHIDA S, IWAMOTO I: IFN-alpha inhibits antigen-induced eosinophil and CD4+ T-cell recruitment into tissue. brununol. (1994) 153:1264–1270.
   Google Scholar
• WANG K, SCHEEL-TOELLNER D, WONG SH et al.: Inhibition of neutrophil apoptosis by type I IFN depends on the cross-talk between phosphoinositol 3-kinase, protein kinase C-delta, and NF-kappa B signalling pathways. I brununol (2003) 171(2):1035–1041.
   Google Scholar
• LOMBARDI G, DUNNE PJ, SCHEEL-TOELLNER D et al.: Type I IFN maintains the survival of anergic CD4+ T cells. I brununol. (2000) 165(7):3782–3789.
   Google Scholar
• SCHEEL-TOELLNER D, PILLING D, AKBAR AN et al.: Inhibition of T cell apoptosis by IFN-beta rapidly reverses nuclear translocation of protein kinase C-delta. Ear: I brununol. (1999) 29(8):2603–2612.
   PubMed Web of Science ®Google Scholar
• BIRON CA: Interferons alpha and beta as immune regulators-a new look. brununih, (2001) 14:661–664.
   Google Scholar
• LE BON A, TOUGH DF: Links between innate and adaptive immunity via type I interferon. Cup: Opin. Inainunol. (2002) 14:432–436.
   PubMed Web of Science ®Google Scholar
• SUN S, ZHANG X, TOUGH DF, SPRENT J: Type I interferon-mediated stimulation of T cells by CpG DNA. I Exp. Merl (1998) 188(12):2335–2342.
   PubMed Web of Science ®Google Scholar
• CELLA M, JARROSSAY D, FACCHETTI F et al.: Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. (1999) 5:919–923.
   PubMed Web of Science ®Google Scholar
• ••Identification of the major type IIFN-producing cell type.
   Google Scholar
• SIEGAL FP, KADOWAKI N, SHODELL M et al.: The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 284: 1835-1837.
   Google Scholar
• ASSELIN-PATUREL C, BOONSTRA A, DALOD M et al.: Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. brununol. (2001) 2:1144–1150.
   PubMed Web of Science ®Google Scholar
• NAKANO H, YANAGITA M, GUNN MD: CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. I Exp. Med. (2001) 194:1171–1178.
   PubMed Web of Science ®Google Scholar
• DIEBOLD SS, MONTOYA M, UNGER H et al.: Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature (2003) 424:324–328.
   PubMed Web of Science ®Google Scholar
• KADOWAKI N, ANTONENKO S, LAU JY, LIU YJ: Natural interferon alpha/ beta-producing cells link innate and adaptive immunity. I Exp. Med. (2000) 192:219–226.
   PubMed Web of Science ®Google Scholar
• ZOU W, MACHELON V, COULOMB-L'HERMIN A et al.: Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. (2001) 7(12):1339–1346.
   Google Scholar
• VERMI W, BONECCHI R, FACCHETTI F et al.: Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. I Pathol. (2003) 200(2):255–268.
   Web of Science ®Google Scholar
• MOHTY M, JARROSSAY D, LAFAGE-POCHITALOFF M et al: Circulating blood dendritic cells from myeloid leukaemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood (2001) 98(13):3750–3756.
   PubMed Web of Science ®Google Scholar
• MOHTY M, ISNARDON D, VEY N et al: Low blood dendritic cells in chronic myeloid leukaemia patients correlate with loss of CD34+/CD38- primitive haematopoietic progenitors. Br. Haeinatol (2002) 119(1):115–118.
   PubMed Web of Science ®Google Scholar
• MOHTY M, VIALLE-CASTELLANO A, NUNES JA, ISNARDON D, OLIVE D, GAUGLER B: IFN-alpha skews monocyte differentiation into toll-like receptor 7-expressing dendritic cells with potent functional activities. I Inununol. (2003) 171:3385–3393.
   Google Scholar
• MONTOYA M, SCHIAVONI G, MATTEI F, GRESSER I, BELARDELLI F, BORROW P, TOUGH DF: Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood (2002) 99:3263–3271.
   PubMed Web of Science ®Google Scholar
• SANTINI SM, LAPENTA C, LOGOZZI M et al.: Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. (2000) 191:1777–1788.
   PubMed Web of Science ®Google Scholar
• NAGAI T, DEVERGNE 0, MUELLER TF, PERKINS DL, VAN SEVENTER JM, VAN SE VENTER GA: Timing of IFN-beta exposure during human dendritic cell maturation and naïve Th cell stimulation has contrasting effects on Thl subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines and IL-18 in naïve Th cell differentiation. Inainunol. (2003) 171(10):5233–5243.
   Google Scholar
• LAPENTA C, SANTINI SM, LOGOZZI M et al.: Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J. Exp. Med. (2003) 198:361–367.
   PubMed Web of Science ®Google Scholar
• HONDA K, SAKAGUCHI S, NAKAJIMA C et al.: Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc. Natl Acad. Sci. USA (2003) 100:10872–10877.
   PubMed Web of Science ®Google Scholar
• SANTODONATO L, D'AGOSTINO G, NISINI R et al.: Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response. Immunol (2003) 170:5195–5202.
   Google Scholar
• LE BON A, HART N, ROSSMANN C et al.: Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol (2003) 4:1009–1015.
   PubMed Web of Science ®Google Scholar
• BLANCO P, PALUCKA AK, GILL M, PASCUAL V, BANCHEREAU J: Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (2001) 294:1540–1543.
   PubMed Web of Science ®Google Scholar
• PASCUAL V, BANCHEREAU J, PALUCKA AK: The central role of dendritic cells and interferon-alpha in SLE. Carr. Opin. Rheumatol. (2003) 15:548–556.
   PubMed Web of Science ®Google Scholar
• SANTIAGO-RABER ML, BACCALA R, HARALDSSON KM et al.: Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. (2003) 197:777–788.
   PubMed Web of Science ®Google Scholar
• FUSS IJ, NEURATH ME BOIRIVANT M et al.: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol (1996) 157:1261–1270.
   Google Scholar
• ••Key paper demonstrating the importanceof another Th2 cytokine (IL-5) in UC, providing the basis for the concept of a Th2-linked disease.
   Google Scholar
• GASCHE C, REINISCH W, VOGELSANG H et al.: Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's diseases. Dig. Dis. Sa. (1995) 40:800–804.
   PubMed Web of Science ®Google Scholar
• SUMER N, PALABIYIKOGLU M: Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur. J. Gastroenterol Hepatol (1995) 7:597-602. First report demonstrating efficacy of IFN-a in UC.
   Google Scholar
• MADSEN SM, SCHLICHTING P, DAVIDSEN B et al.: An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am. J. Gastroenterol (2001) 96(6):1807–1815.
   PubMed Web of Science ®Google Scholar
• ••Important study showing that IFN-atherapy might be superior to local steroid therapy in left-sided UC.
   Google Scholar
• SCHANDENE L, DEL PRETE GE COGAN E et al.: Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T -cells. J. Clin. Invest. (1996) 97:309–315.
   Google Scholar
• MUSCH E, ANDUS T, MALEK M: Induction and maintenance of clinical remission by interferon beta in patients with steroid-refractory active ulcerative colitis: an open long-term pilot trial. Aliment. Pharmacol The]: (2002) 16(7):1233–1239.
   PubMed Web of Science ®Google Scholar
• •First report supporting a role for IFN-I3 therapy in UC.
   Google Scholar
• NIKOLAUS S, RUTGEERTS P, FED ORAK R et al.: Interferon beta- la in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut (2003) 52(9):1286–1290.
   Google Scholar
• ••First controlled study in UC showing superior efficacy of IFN-I3 compared to placebo.
   Google Scholar
• NOVICK D, COHEN B, RUBINSTEIN M: The human interferon alpha/beta receptor: characterization and molecular cloning. Cell (1994) 77:391–400.
   PubMed Web of Science ®Google Scholar
• DA SILVA AJ, BRICKELMAIER M, MAJEAU GR et al: Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b versus IFN-beta la: understanding the functional relationship between distinct type I interferons that act through a common receptor. J Interferon Cytokine Res. (2002) 22:173–188.
   PubMed Web of Science ®Google Scholar
• TILG H, VOGELSANG H, LUDWICZEK 0 et al.: A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut (2003) 52(12):1728–1733.
   Google Scholar
• ••First placebo-controlled study withpegylated IFN-a in UC.
   Google Scholar
• GNIADEK P, AKTAS 0, WANDINGER KP et al.: Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients. J. Neuroimmunol (2003) 137(1–2):187–196.
   Google Scholar
• SOLDAN SS, RETUERTO Al, SICOTTE NL, VOSKUHL RR: Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J. Immunol (2003) 171:6267–6274.
   PubMed Web of Science ®Google Scholar
• WIESEMANN E, KLATT J, WENZEL C, HEIDENREICH F, WINDHAGEN A: Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis. Clin. Exp. Immunol (2003) 133:454–460.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the role of Th2 cytokines with respect to treatment success in MS.
   Google Scholar
• MATHEU V, TRESCHOW A, NAVIKAS V, ISSAZADEH-NAVIKAS S: Upregulation of B7 molecules (CD80 and CD86) and exacerbation of eosinophilic pulmonary inflammatory response in mice lacking the IFN-beta gene. J Allergy Clin. Immunol (2003) 111:550–557.
   PubMed Web of Science ®Google Scholar
• BUFE A, GEHLHAR K, GRAGE-GRIEBENOW E, ERNST M: Atopic phenotype in children is associated with decreased virus-induced interferon-alpha release. hat. Arch. Allergy Pharmacol (2002) 127(1):82–88.
   Web of Science ®Google Scholar
• KANAZAWA H, MAMOTO T, HIRATA K, YOSHIKAWA J: Interferon therapy induces the improvement of lung function to inhaled corticosteroid therapy in asthmatic patients with chronic hepatitis C virus infection: a preliminary study. Chest (2003) 123(2):600–603.
   PubMed Web of Science ®Google Scholar
• SIMON HU, SEELBACH H, EHMANN R, SCHMITZ M: Clinical and immunological effects of low-dose IFN-alpha-26 treatment in patients with corticosteroid-resistant asthma. Allergy (2003) 58(12):1250–1255.
   PubMed Web of Science ®Google Scholar
• ••Key paper paving the way for futurestudies with type I IFNs in allergic asthma.
   Google Scholar
• TATSIS E, SCHNABEL A, GROSS WL: Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann. Intern. Med (1998) 129(5):370–374.
   PubMed Web of Science ®Google Scholar
• REISSIG A, FORSTER M, MOCK B, SCHILDER C, KROEGEL C: Interferon-alpha treatment of the Churg-Strauss syndrome. Dsch. Med. Wochenschr. (2003) 128(27):1469.
   PubMedGoogle Scholar
• GROSS WL: Churg-Strauss syndrome: update on recent developments. Carr: Opin. Rheumatol (2002) 14(1):11–14.
   PubMed Web of Science ®Google Scholar
• O'DUFFY JD, CALAMIA K, COHEN S et al.: Interferon-alpha treatment of Behcet's disease. J. Rheumatol (1998) 25:1938–1944.
   Google Scholar
• GEORGIOU S, MONASTIRILI A, PASMATZI A, GARTAGANIS S, GOERZ G, TSAMBAOS DJ: Efficacy and safety of systemic recombinant interferon-alpha in Behcet's disease. J. Intern. Med. (1998) 243:367–372.
   PubMed Web of Science ®Google Scholar
• KOTTER I, ZIERHUT M, ECKSTEIN AK et al.: Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br. J. Ophthalinol (2003) 87(4):423–431.
   PubMed Web of Science ®Google Scholar
• ••Important study supporting the majortherapeutic role for IFN-a in this disorder.
   Google Scholar
• GRANOWITZ EV, SAGET BM, WANG MZ, DINARELLO CA, SKOLNIK PR: Interleukin-1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin-1 receptor antagonist and tumor necrosis factor binding protein type 1. Ma Med. (1995) 1:667–677.
   PubMed Web of Science ®Google Scholar
• MOLLER C, BERGMANN KF, GERIN JL, KORBA BE: Production of hepatitis B virus by stably transfected monocytic cell line U-937: a model for extrahepatic hepatitis B virus replication. .1. Infect. Dis. (1992) 165:929–933.
   PubMed Web of Science ®Google Scholar
• GARCIA-MONZON C, GARCIA-BUEY L, GARCIA-SANCHEZ A, PAJARES JM, MORENO-OTERO R: Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interferonalfa-2b. Gastroenterology (1993) 105:462–469.
   PubMed Web of Science ®Google Scholar
• INAGAKI Y, NEMOTO T, KUSHIDA M et al.: Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology (2003) 38(4):890–899.
   PubMed Web of Science ®Google Scholar
• POYNARD T, MCHUTCHINSON J, MANNS M et al.: Impact of pegylated interferon alfa-26 and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology (2002) 122(5):1303–1313.
   PubMed Web of Science ®Google Scholar
• KUHL U, PAUSCHINGER M, SCHWIMMBECK PL et al.: Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular function. Circulation (2003) 107(22):2793–2798
   PubMed Web of Science ®Google Scholar
• ••First report of the efficacy of a type I IFNin myocardial virus-related diseases.
   Google Scholar
• VELDHUIS WB, FLORIS S, VAN DER MEIDE PH et al.: Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption. I Gem& Blood Dow Metal,. (2003) 23(9):1060–1069.
   Google Scholar
• TEN HOVE T, VAN MONTFRANS C, PEPPELENBOSCH MP, VAN DEVENTER SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut (2002) 50(2):206–211.
   PubMed Web of Science ®Google Scholar
• TIEDE I, FRITZ G, STRAND S et al: CD28-dependent Racl activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. I. Clin. Invest. (2003) 111:133–1145.
   Web of Science ®Google Scholar